1. Home
  2. MDWD vs FCEL Comparison

MDWD vs FCEL Comparison

Compare MDWD & FCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • FCEL
  • Stock Information
  • Founded
  • MDWD 2000
  • FCEL 1969
  • Country
  • MDWD Israel
  • FCEL United States
  • Employees
  • MDWD N/A
  • FCEL N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • FCEL Industrial Machinery/Components
  • Sector
  • MDWD Health Care
  • FCEL Energy
  • Exchange
  • MDWD Nasdaq
  • FCEL Nasdaq
  • Market Cap
  • MDWD 184.8M
  • FCEL 201.3M
  • IPO Year
  • MDWD 2014
  • FCEL 1992
  • Fundamental
  • Price
  • MDWD $20.15
  • FCEL $7.68
  • Analyst Decision
  • MDWD Strong Buy
  • FCEL Hold
  • Analyst Count
  • MDWD 1
  • FCEL 6
  • Target Price
  • MDWD $25.00
  • FCEL $22.78
  • AVG Volume (30 Days)
  • MDWD 78.0K
  • FCEL 1.1M
  • Earning Date
  • MDWD 03-20-2025
  • FCEL 03-06-2025
  • Dividend Yield
  • MDWD N/A
  • FCEL N/A
  • EPS Growth
  • MDWD N/A
  • FCEL N/A
  • EPS
  • MDWD N/A
  • FCEL N/A
  • Revenue
  • MDWD $19,720,000.00
  • FCEL $112,132,000.00
  • Revenue This Year
  • MDWD $10.15
  • FCEL $64.70
  • Revenue Next Year
  • MDWD $25.62
  • FCEL $3.10
  • P/E Ratio
  • MDWD N/A
  • FCEL N/A
  • Revenue Growth
  • MDWD N/A
  • FCEL N/A
  • 52 Week Low
  • MDWD $11.04
  • FCEL $5.45
  • 52 Week High
  • MDWD $24.00
  • FCEL $45.60
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 57.75
  • FCEL 37.40
  • Support Level
  • MDWD $18.73
  • FCEL $7.10
  • Resistance Level
  • MDWD $19.73
  • FCEL $8.07
  • Average True Range (ATR)
  • MDWD 0.78
  • FCEL 0.57
  • MACD
  • MDWD 0.02
  • FCEL -0.13
  • Stochastic Oscillator
  • MDWD 66.35
  • FCEL 17.20

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About FCEL FuelCell Energy Inc.

FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.

Share on Social Networks: